Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Revolution Medicines, Inc. RVMD
$25.51
-$0.11 (-0.43%)
На 18:01, 12 мая 2023
+21.52%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2717283600.00000000
-
week52high
31.37
-
week52low
14.08
-
Revenue
35380000
-
P/E TTM
-9
-
Beta
1.44541900
-
EPS
-3.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 17 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 авг 2022 г. |
| B of A Securities | Neutral | 20 мая 2022 г. | |
| Stifel | Buy | Hold | 01 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 ноя 2021 г. |
| Oppenheimer | Outperform | 21 окт 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 08 ноя 2022 г. |
| Needham | Buy | 14 дек 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Horn Margaret A | D | 61292 | 1220 | 19 дек 2022 г. |
| Kelsey Stephen Michael | D | 287599 | 1220 | 19 дек 2022 г. |
| Wang Xiaolin | D | 30527 | 708 | 19 дек 2022 г. |
| Anders Jack | D | 29298 | 658 | 19 дек 2022 г. |
| Horn Margaret A | D | 0 | 17767 | 07 ноя 2022 г. |
| Horn Margaret A | D | 17767 | 17767 | 31 окт 2022 г. |
| Horn Margaret A | D | 35534 | 17768 | 26 окт 2022 г. |
| Anders Jack | D | 29956 | 449 | 19 сент 2022 г. |
| Horn Margaret A | D | 62512 | 1267 | 19 сент 2022 г. |
| Kelsey Stephen Michael | D | 288819 | 1267 | 19 сент 2022 г. |
Новостная лента
Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice
Zacks Investment Research
02 февр 2023 г. в 13:33
Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Revolution Medicines to Participate in Upcoming Investor Conferences
GlobeNewsWire
02 февр 2023 г. в 07:00
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be the featured speaker in fireside chats at the Guggenheim Healthcare Talks 2023 Oncology Conference and the SVB Securities Global Biopharma Conference.
Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
Zacks Investment Research
12 янв 2023 г. в 04:31
Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Revolution Medicines: Highly Differentiated Offering Gaining Traction
Seeking Alpha
07 дек 2022 г. в 16:35
Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's standing up well in safety, efficacy. The company is well-capitalized to continue operations and clinical advancements.
Revolution Medicines to Participate in Upcoming Investor Conferences
GlobeNewsWire
09 ноя 2022 г. в 16:05
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the 5th Annual Evercore ISI HealthCONx Conference.